This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Seropositive rheumatoid arthritis, unspecified상세불명의 혈청검사양성 류마티스관절염

Contents and key points
ItemDetails
A. Classification codesICD-10: M05.9 | Special Copayment Reduction: V223 (severe intractable disease, 5 years)
B. SynonymsNone (seropositive RA, classification undetermined)
C. Adult onsetAdult onset very high — seropositive RA presents almost without exception in adults (40s–70s). It is a provisional classification code, and reclassification after confirmed diagnosis is the rule.
1. HistorySee main text
2. CausesSee main text
3. GeneticsSee main text
4. General epidemiologySee main text
5. PathophysiologySee main text
6. SymptomsSee main text
7. SignsSee main text
8. ScreeningSee main text
9. DiagnosisSee main text
10. TreatmentSee main text
11. PrognosisSee main text
12. PreventionSee main text
13. ReferencesSee main text

1. History

Rheumatoid arthritis (RA) was named by Garrod in 1858, and the treatment paradigm developed with the introduction of corticosteroids in the 1940s-50s, the establishment of MTX in the 1980s, and the biologic revolution of the 2000s. The joint ACR/EULAR classification criteria were established in 2010.

M05.9 is a provisional code for cases in which seropositive RA has been confirmed but the specific subtype among M05.0–M05.8 has not been identified. The rule is to reclassify into a specific subtype promptly.


2. Causes

The cause of RA is the combined action of genetic predisposition such as the HLA-DRB1 shared epitope, PTPN22, and PADI4; environmental factors such as smoking and periodontal infection; and breakdown of immune tolerance to citrullinated autoantigens. TNF-α, IL-1β, IL-6, and IL-17 are the main inflammatory cytokines.


3. Genetics

Carrying the HLA-DRB1 shared epitope (DRB1*04:01, *04:04, *01:01) increases the risk of ACPA-positive RA several-fold. PTPN22 R620W, PADI4 (East Asians), STAT4, CTLA4, and CCR6 are susceptibility genes.


4. General epidemiology

RA prevalence is 0.5-1% worldwide and about 0.7-1% in Korea. It is 2-3 times more common in women than in men and occurs most often in the 40s-60s. Prognosis has improved markedly since the introduction of biologics and JAK inhibitors.


5. Pathophysiology

ACPA/RF formation in the preclinical stage → synovial deposition of immune complexes and complement activation → chronic synovial inflammation (TNF-α, IL-1β, IL-6, IL-17) → RANKL-mediated osteoclast activation (bone erosion) → cartilage loss by MMPs.


6. Symptoms

Same as the symptoms of M05.8. Polyarticular symmetric arthritis, morning stiffness, joint swelling and tenderness, and systemic symptoms occur.


7. Signs

RF-positive and/or ACPA-positive. Elevated CRP/ESR. Synovial thickening confirmed by joint ultrasound or MRI. M05.9 is a provisional code used before specific subtype classification has been made.


8. Screening

If there is a family history of RA, morning stiffness, or symmetric small-joint swelling, perform RF, ACPA, CRP, and CBC. Prompt referral to rheumatology to establish the final classification and treatment plan.


9. Diagnosis

Seropositive RA is confirmed by the 2010 ACR/EULAR classification criteria (total score of 6 or more) plus RF or ACPA positivity. Further evaluation attempts subtype classification into M05.0–M05.8, and the case is reclassified into a specific subtype. Exclude infectious arthritis, reactive arthritis, psoriatic arthritis, SLE, gout, etc.


10. Treatment

T2T principle: Target clinical remission by DAS28. csDMARD: MTX 15-25 mg/week (first line). bDMARD: anti-TNF (etanercept, adalimumab, etc.), abatacept, rituximab, tocilizumab/sarilumab. tsDMARD: JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Steroids are used at low dose for a short period when inducing remission.


11. Prognosis

Since the introduction of biologics, functional outcomes and mortality in RA have improved markedly. Early aggressive treatment (window of opportunity) is key to determining long-term prognosis. Poor prognostic factors: high ACPA/RF titers, polyarticular involvement, early bone erosion.


12. Prevention

Smoking cessation is the key to preventing ACPA-positive RA. Prevent joint damage with early diagnosis and aggressive DMARD treatment. Tuberculosis screening is essential before starting biologics. Pneumococcal, influenza, and herpes zoster vaccinations are recommended.


13. References

  1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
  2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum. 2010;62(9):2569-2581.
  3. Smolen JS, Landewé RBM, et al. EULAR recommendations for RA management: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
  4. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337.
  5. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183-196.
  6. Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1-ITC16.
  7. Singh JA, Saag KG, Bridges SL, et al. 2015 ACR Guideline for Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
  8. Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(1):35-40.
  9. Kim SK, Park SH. Rheumatoid arthritis in Korea. J Korean Med Assoc. 2013;56(2):126-131.
  10. Koh JH, Park EH, Kim K, et al. Incidence and prevalence of RA in South Korea. Rheumatol Int. 2017;37(9):1509-1514.